Compound library
Each page carries the same structure: mechanism, evidence, typical dosing, reported side effects, legal status, and how confident anyone can be.
Last reviewed September 2026 ยท No commercial relationship with any manufacturer
Semaglutide
FDA approvedGLP-1 agonist, weekly. The most studied of the group in humans.
Tirzepatide
FDA approvedDual GIP and GLP-1 agonist. Larger average weight change in trials.
Retatrutide
InvestigationalTriple agonist still in phase 3. Not legally available to prescribe.
BPC-157
Not approvedTissue-repair claims rest almost entirely on animal studies.
TB-500
Not approvedThymosin beta-4 fragment. Preclinical evidence only; banned in sport.
CJC-1295 / Ipamorelin
Not approvedGrowth hormone secretagogues, usually sold stacked together.
Sermorelin
Prescribed off-labelGHRH analogue used in some clinics for growth hormone assessment.
NAD+
SupplementA coenzyme, not a peptide. Marketing claims run well past the data.
Glutathione
Not approvedThe body's main antioxidant, sold as an IV drip. Poorly absorbed by mouth and short on outcome evidence.
MIC + B12
Not approvedLipotropic fat burner shots. Not a peptide, and no trial has shown they cause weight loss.